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A 31-year-old, gravida 2, para 1, woman was referred
for genetic counseling at 33 weeks’ gestation because
of fetal ascites and fetal hepatosplenomegaly detected
at 32 weeks’ gestation. Level II ultrasound at 33 weeks’
gestation revealed a singleton fetus with fetal biometry
equivalent to 31 weeks’ gestation, fetal ascites and he-
patosplenomegaly (Figure 1). Spontaneous resolution
of fetal ascites with persistent hepatosplenomegaly was
noted at 34 weeks’ gestation (Figure 2). Cordocentesis
at 34 weeks’ gestation revealed a fetal karyotype of
46,XX,der(13;21)(q10;q10),+21 (Figure 3). The mater-
nal karyotype was 45,XX,der(13;21)(q10;q10) (Figure
3). The full blood count revealed a marked leukocyto-
sis with a white cell count of 24.69 × 103 μL with 30%
blast cells and a hemoglobin level of 15.1 g/dL. The
blood smear revealed large undifferentiated blast cells
with fine granularity of the cytoplasm and large irregu-
lar nuclei representing transient abnormal myelopoiesis
(TAM) (Figure 4). Intrauterine fetal death occurred at
36 weeks’ gestation, and a 2,294-g dead female fetus
with characteristic features of Down syndrome was
delivered. Molecular analysis of the GATA1 gene using
fetal tissues revealed that there was no mutation in the
GATA1 gene.
Transient abnormal myelopoiesis (TAM), also known
as transient myeloproliferative disorder or transient
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Figure 1. Prenatal ultrasound at 32 weeks’ gestation shows:
(A) hepatosplenomegaly, and (B) fetal ascites.
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leukemia, is a hematologic disorder that is confined to
Down syndrome and presents in the fetal or neonatal
period [1]. Clinical and laboratory features of TAM
in neonates with Down syndrome include pericardial
effusion, ascites, pulmonary edema, hepatosplenomegaly,
hepatic fibrosis, liver failure, obstructive jaundice,
leukocytosis, persistent peripheral blood blast cells,
abnormal platelet counts, and vesicopapular skin
rashes [1]. About 10% of newborn infants with Down
syndrome develop TAM [2], and 20–30% of TAM babies
will develop myeloid leukemia of Down syndrome, which
is an acute leukemia [3]. GATA1 mutations have been
found in Down syndrome with leukemia [4–8]. The
present case was not associated with mutations in the
GATA1 gene. The sonographic findings of TAM cases
diagnosed during fetal life include hepatosplenomegaly,
pericardial effusion, ascites, hydrops fetalis, skin
edema, polyhydramnios, and cardiomegaly [9]. Zerres
et al [10] first reported the prenatal diagnosis of TAM
and 47,XX,+21 in a fetus with nonimmune hydrops
fetalis with ascites and pericardial effusion at 36
weeks’ gestation. After birth, the neonate survived and
the diagnosis of acute leukemia was confirmed by
blood smear and bone marrow. Foucar et al [11]
reported fetal ascites at 31 weeks’ gestation in a fetus
with TAM and 47,XX,+21. The fetus was delivered at
32 weeks’ gestation with massive edema but survived
after intensive pediatric care. Macones et al [12]
reported fetal ascites, hydrops fetalis, polyhydramnios,
an endocardial cushion defect, shortened femurs and
hepatosplenomegaly at 28 weeks’ gestation in a fetus
with TAM and 47,XY,+21. Intrauterine fetal death
occurred at 29 weeks’ gestation. Strobelt et al [13]
reported the prenatal diagnosis of pericardial effusion
and hepatosplenomegaly at 31 weeks’ gestation in a
fetus with TAM and 47,XY,+21. At 31 weeks’ gestation,
worsening of pericardial effusion and a thin rim of
ascites were noted. A fetal pericardiocentesis was per-
formed to remove 40 mL of pericardial fluid. Thereafter,
weekly sonographic examinations showed no re-accu-
mulation of the pericardial effusion, disappearance of
the thin rim of ascites, and stable hepatosplenomegaly.
The fetus was delivered and survived at 35 weeks’ ges-





Figure 2. Prenatal ultrasound at 34 weeks’ gestation shows: (A) hepatosplenomegaly in the longitudinal section, and 
(B) splenomegaly in the transverse section with resolution of fetal ascites. L = liver, S = spleen.
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Figure 3. (A) The maternal karyotype shows a balanced robertsonian translocation of 45,XX,der(13;21)(q10;q10). 
(B) The fetal karyotype shows an unbalanced robertsonian translocation of 46,XX,der(13;21)(q10;q10),+21.
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of fetal hepatosplenomegaly and marked pericardial
effusion at 26 weeks’ gestation in a fetus with TAM
and 47,XY,+21. Additional pleural effusion, ascites
and skin edema were noted at 27 weeks’ gestation.
Fetal hydrops, hepatosplenomegaly and ascites persisted
till 31 weeks’ gestation when intrauterine fetal death
occurred. Smrcek et al [15] reported the prenatal diag-
nosis of hepatosplenomegaly, ascites, skin edema, car-
diomegaly and pericardial effusion at 30 weeks’ gestation
in a fetus with TAM and 47,XY,+21. Intrauterine fetal
death occurred 10 hours after the diagnosis. The pres-
ent case provides evidence that fetal ascites associated
with TAM and hepatosplenomegaly may resolve spon-
taneously during fetal life. All reported cases of prena-
tally detected Down syndrome with TAM are free trisomy
21 (47,XY,+21 or 47,XX,+21). We have presented the
first report of a prenatal diagnosis of an unbalanced
robertsonian translocation involving chromosome 21
associated with TAM because of the abnormal sono-
graphic findings of hepatosplenomegaly and ascites.
Prenatal diagnosis of hepatosplenomegaly with or without
ascites should alert the clinician to the possibility of
familial trisomy 21, and prompt cytogenetic analysis
and genetic counseling.
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